Pulmonary Endarterectomy for Chronic Thromboembolic Pulmonary Hypertension: An STS Database Analysis.

BACKGROUND: Chronic thromboembolic pulmonary hypertension is optimally treated by pulmonary thromboendarterectomy (PEA). Treatment effectiveness has been evaluated principally using single-center series. Data from The Society of Thoracic Surgeons Adult Cardiac Surgery Database were used to evaluate a volume-outcomes relationship for PEA. METHODS: Circulatory arrest procedures performed between 2012 and 2018 were identified through a Society of Thoracic Surgeons Adult Cardiac Surgery Database Participant User File. For descriptive purposes, total center procedural volume categories were computed: low (0-75th percentile, <16); medium (76-95th percentile, 16-100); high (>95th percentile, >100). Mixed effect modeling was used to evaluate the effect of center procedural volume (modeled continuously) on operative mortality, adjusting for preoperative risk factors, with centers as a random effect. RESULTS: There were 1358 cases performed across 64 centers (low volume: n = 49 of 172; medium volume: n = 12 of 527; high volume: n = 3 of 659), with 42 centers performing less than 10 operations during the period. Procedural volume increased 2.6-fold between 2012 and 2018 (94 vs 339), with 79% of the change in volume accounted for by 4 centers. The median preoperative pulmonary artery systolic value was 74 (interquartile range, 57-88) mm Hg, with no difference (P = .55) by center volume categories. In unadjusted analysis, patients at high-volume centers required fewer transfusions, had shorter ventilator and intensive care unit duration, had a lower frequency of postoperative extracorporeal membrane oxygenation, and trended toward lower mortality (2.1% vs 5.2%; P = .051). Operative mortality was lower at higher-volume centers (adjusted odds ratio [1-case increase], 0.997; 95% confidence interval, 0.994-1.0; P = .025). CONCLUSIONS: Most PEA procedures are performed among a small number of centers, with high-volume hospitals having favorable outcomes. These data suggest a potential role for PEA regionalization.

Surgical explantation of transcatheter aortic bioprostheses: Results and clinical implications.

OBJECTIVE: Despite the rapid adoption of transcatheter aortic valve replacement (TAVR) and worldwide interest in its implantation, TAVR valve explantation has not been well described. METHODS: We retrospectively reviewed 1442 consecutive patients who underwent a TAVR procedure between 2011 and 2019, in which TAVR explantation was performed in 15 patients (1.0%). In addition, 2 patients from outside institutions also underwent TAVR explantation at our institution. We reviewed the clinical details of these 17 patients. RESULTS: The frequency of TAVR explant increased over time from 0 to 1 during the period from 2011 to 2015 to 6 in 2019. The mean age was 73.0 ± 9.3 years. The majority of patients (88.2%) were in New York Heart Association functional class IV heart failure. The Society of Thoracic Surgeons Predicted Risk of Mortality score was significantly higher at the time of explantation than at the time of the original TAVR (3.5% vs 9.9%; P < .001). The indication for explantation included structural valve degeneration (23.5%), severe paravalvular leak (41.2%), TAVR procedure-related complications (23.5%), endocarditis (5.9%), and bridge-to-definitive surgery (5.9%). Neoendothelialization of the TAVR valve into the aortic wall requiring intense aortic endarterectomy was noted in all 5 of the TAVR valves older than 1 year, in which 2 (40%) required unplanned aortic root repair. There were 2 (11.8%) in-hospital mortalities. CONCLUSIONS: Surgical TAVR valve explant is increasing and may become common in the near future. The clinical effects of explanting chronically implanted valves with the potential need for aortic repair is not negligible. These data should be used to more appropriately select TAVR candidates as TAVR practices expand into younger and lower risk patients.

Imaging, Surgical, and Pathology Findings of a Myxoid Aortic Sarcoma: When Distal Embolization Uncovers a Bigger Problem.

Aortic sarcomas are a very rare condition typically characterized by a deceiving presentation. Making a correct diagnosis is based on the application of an algorithm which allows to identify the primary disease site and to obtain a tissue diagnosis. Surgical aortic resection with adjuvant therapy offers the best palliation, particularly in cases of well-differentiated tumors with no evidence of diffuse metastatic spread.